Monday, October 22, 2007
Bioenvision, Inc. announced yesterday that its stockholders had voted to approve the acquisition of the company by Genzyme at a reconvened meeting of its shareholders. Fifty-six percent of Bioenvision's shares of common stock and preferred stock supported the merger. This represented approximately 67 percent of the total shares voted.
For my prior posts on this deal see: